Novo Nordisk A/S (NONOF)
| Market Cap | 359.92B |
| Revenue (ttm) | 40.47B |
| Net Income (ttm) | 14.17B |
| Shares Out | n/a |
| EPS (ttm) | 3.17 |
| PE Ratio | 25.41 |
| Forward PE | n/a |
| Dividend | 0.52 (0.66%) |
| Ex-Dividend Date | Aug 15, 2024 |
| Volume | 100 |
| Average Volume | 41,596 |
| Open | 81.00 |
| Previous Close | 80.22 |
| Day's Range | 81.00 - 82.23 |
| 52-Week Range | 78.35 - 149.55 |
| Beta | 0.17 |
| RSI | 38.77 |
| Earnings Date | Feb 5, 2025 |
About Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin... [Read more]
Financial Performance
In 2023, Novo Nordisk's revenue was 232.26 billion, an increase of 31.26% compared to the previous year's 176.95 billion. Earnings were 83.68 billion, an increase of 50.71%.
Financial numbers in DKK Financial StatementsNews
Shareholders that lost money on Novo Nordisk A/S(NVO) should contact Levi & Korsinsky about Securities Fraud Investigation - NVO
NEW YORK, NY / ACCESS Newswire / January 23, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Novo Nordisk A/S ("Novo Nordisk A/S") (NYSE:NVO) concerning possible v...
Novo Nordisk Inks License Agreement For Sickle Cell Disease Candidate
On Wednesday, IMMvention Therapeutix, Inc. announced a strategic collaboration and license agreement with Novo Nordisk A/S (NYSE: NVO) to co-develop oral therapies for sickle cell disease (SCD) and o...
IMMvention Therapeutix enters collaboration with Novo Nordisk for sickle cell disease therapies
IMMvention Therapeutix partners with Novo Nordisk to develop oral therapies for sickle cell disease and other chronic conditions.
IMMvention Therapeutix Enters Strategic Collaboration with Novo Nordisk to Develop Oral Therapies for Sickle Cell Disease and Other Chronic Diseases
DURHAM, N.C., Jan. 22, 2025 (GLOBE NEWSWIRE) -- IMMvention Therapeutix, Inc ., an early-stage biotechnology company focused on discovering and developing human therapeutics, today announced a strategi...
Novo Nordisk A/S Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - NVO
NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Novo Nordisk A/S ("Novo Nordisk A/S") (NYSE:NVO) concerning possible v...
Moody's Upgrades Novo Nordisk's Credit Rating Amid Strong Growth
Moody's Upgrades Novo Nordisk's Credit Rating Amid Strong Growth
Healthy Returns: Biotech and pharma M&A is off to a good start in 2025 — but will it last?
Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and Goliath dynamic” in 2024, report says.
There is a 'valley of death' in European research and innovation, says CEO of Novo Nordisk Foundation
Mads Krogsgaard Thomsen, CEO of Novo Nordisk Foundation, discusses European competitiveness.
$1000 Invested In Novo Nordisk 10 Years Ago Would Be Worth This Much Today
Novo Nordisk (NYSE: NVO) has outperformed the market over the past 10 years by 1.92% on an annualized basis producing an average annual return of 13.38%. Currently, Novo Nordisk has a market capitali...
Novo, Lilly Weight-Loss Drugs Reduce Risk of Alzheimer's, Study Shows. What It Means for the Stocks.
Weight-loss medications have exploded in popularity but the health-benefits go beyond obesity.
Will Medicare End Ozempic Maker Novo Nordisk's Obesity Drug Boom?
LVMH Surges Past Novo Nordisk as Arnault's Wealth Skyrockets--Is Luxury Back on Track?
LVMH Surges Past Novo Nordisk as Arnault's Wealth Skyrockets--Is Luxury Back on Track?
Investors who Lost Money on Novo Nordisk A/S Should Contact Levi & Korsinsky About an Ongoing Investigation - NVO
NEW YORK CITY, NY / ACCESS Newswire / January 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Novo Nordisk A/S ("Novo Nordisk A/S") (NYSE:NVO) concerning possi...
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 20 January 2025 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Coun...
LVMH dethrones Novo Nordisk as Europe’s most valuable company as Bernard Arnault adds $12 billion to net worth in 2025
Novo Nordisk has faced a massive selloff in recent months amid disappointing drug trials and U.S. pressure to cut its prices.
Is Novo Nordisk Stock a Buy?
Dr. Kavita Patel talks impact of GLP-1 price negotiations
Dr. Kavita Patel joins 'Fast Money' to talk what is next for GLP-1 drug makers.
Moderna is a 'trade' on Bird Flu vaccine pop, says Mizuho's Jared Holz
Jared Holz, Mizuho Healthcare Sector strategist, joins 'Closing Bell Overtime' to talk Moderna and Novo Nordisk.
Obesity drugs Ozempic and Wegovy included in US price-cut talks
Novo Nordisk shares hit as government adds blockbuster weight-loss treatments to new round of negotiations
3-Stock Lunch: Intel, Sherwin-Williams & Novo Nordisk
Gina Sanchez, Lido Advisors chief market strategist, joins 'Power Lunch' to discuss stock plays for three stocks.
3-Stock Lunch: Intel, Sherwin-Williams & Novo Nordisk
Gina Sanchez, Lido Advisors chief market strategist, joins 'Power Lunch' to discuss stock plays for three stocks.
Explainer: What Wegovy's inclusion in Medicare price negotiation means for patients, company
The U.S. government on Friday announced a list of 15 prescription medicines targeted for Medicare price negotiations for 2027, which includes Novo Nordisk's blockbuster weight-loss drug Wegovy. Here's...
Novo Nordisk Unusual Options Activity
Whales with a lot of money to spend have taken a noticeably bullish stance on Novo Nordisk . Looking at options history for Novo Nordisk (NYSE: NVO) we detected 21 trades. If we consider the specific...
Stocks making the biggest moves midday: Novo Nordisk, J.B. Hunt, Qorvo and more
These are the stocks posting the largest moves in midday trading.
LVMH overtakes Novo Nordisk as Europe’s most valuable company
Luxury bellwether regains crown as drugmaker slips on concerns it will have to cut weight loss medication prices in US